AbbVie Licenses Nxera's Gut-Targeted EP4 Agonist for IBD in a Deal Worth Up to $1.47B
- AbbVie is licensing Nxera Pharma's EP4 receptor agonist program, aimed at inflammatory bowel disease, with $100 million upfront.
- Development and commercial milestones could add up to $1.37 billion.
- Nxera, through its UK subsidiary, hands over global rights to the gut-targeting program.
💡 Points Based on public reports
AbbVie already owns two big IBD franchises built on IL-23 and JAK inhibition, so a gut-restricted EP4 agonist reads as a mechanism hedge aimed at mucosal healing rather than another immunosuppressant. Upfront is under a tenth of the headline, a typical back-loaded structure. The open question is whether gut restriction holds in patients; EP4 agonists have a history of systemic exposure problems, so early PK and mucosal-biopsy data are what to watch.
AbbVie bets up to $1.47B on Nxera's gut-targeting IBD program ↗